Last reviewed · How we verify

DTaP-HB-PRP~T vaccine + OPV

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-HB-PRP~T vaccine + OPV is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

At a glance

Generic nameDTaP-HB-PRP~T vaccine + OPV
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-HB-PRP~T is a hexavalent vaccine containing inactivated toxoids (diphtheria, tetanus), acellular pertussis antigens, hepatitis B surface antigen, Haemophilus influenzae type b conjugate, combined with oral polio vaccine (OPV) containing live attenuated poliovirus strains. The vaccine triggers both humoral and cell-mediated immune responses to provide protection against these six infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-HB-PRP~T vaccine + OPV

What is DTaP-HB-PRP~T vaccine + OPV?

DTaP-HB-PRP~T vaccine + OPV is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

How does DTaP-HB-PRP~T vaccine + OPV work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.

What is DTaP-HB-PRP~T vaccine + OPV used for?

DTaP-HB-PRP~T vaccine + OPV is indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

Who makes DTaP-HB-PRP~T vaccine + OPV?

DTaP-HB-PRP~T vaccine + OPV is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What drug class is DTaP-HB-PRP~T vaccine + OPV in?

DTaP-HB-PRP~T vaccine + OPV belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP-HB-PRP~T vaccine + OPV in?

DTaP-HB-PRP~T vaccine + OPV is in Phase 3.

What are the side effects of DTaP-HB-PRP~T vaccine + OPV?

Common side effects of DTaP-HB-PRP~T vaccine + OPV include Injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related